MET and non-small cell lung carcinoma: Data with capmatinib and tepotinib indicate that selective type Ib MET inhibitors, which include tepotinib and capmatinib, are valid therapeutic options for NSCLC patients with brain metastases harbouring METex14 skipping mutations.